Subscribe to RSS
DOI: 10.1055/s-0031-1273397
© Georg Thieme Verlag KG Stuttgart · New York
Effektivität einer Augmentationstherapie mit Antipsychotika bei therapieresistenten Zwangsstörungen – eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter Studien
Efficacy of Antipsychotic Augmentation Therapy in Treatment-Resistant Obsessive-Compulsive Disorder – A Meta-Analysis of Double-Blind, Randomised, Placebo-Controlled TrialsPublication History
Publication Date:
01 August 2011 (online)

Zusammenfassung
Da bei der Zwangsstörung nur etwa 40 – 60 % aller Patienten auf Serotonin-Wiederaufnahmehemmer (SRIs) ansprechen, kommt der Evaluation additiver Therapien bei Behandlungsresistenz eine hohe klinische Relevanz zu. Mittels systematischer Literaturrecherche wurden alle doppelblinden, randomisierten, placebokontrollierten Studien erfasst, die die Wirksamkeit einer SRI-Antipsychotika-Kombinationstherapie bei therapieresistenten Zwangsstörungen evaluiert haben. 11 Studien mit insgesamt 356 Teilnehmern wurden identifiziert. Nach der Augmentationsbehandlung erfüllten in den Interventionsgruppen (SRI + Antipsychotikum) signifikant mehr Probanden das Responder-Kriterium (Reduktion im Yale-Brown Obsessive Compulsive Scale [Y-BOCS] ≥ 35 %) als in den Kontrollgruppen (SRI + Placebo) (relatives Risiko = 2,16). Die Subgruppenanalyse zeigte nur für Risperidon eine signifikante Effektivität. Weitere signifikante Unterschiede fanden sich hinsichtlich der Dosierung der Antipsychotika und der Dauer der SRI-Medikation vor der Augmentationsphase.
Abstract
Only 40 – 60 % of all patients with obsessive-compulsive disorder (OCD) respond to serotonin reuptake inhibitors (SRIs). Therefore, the evaluation of additive treatment in the presence of treatment resistance has high clinical relevance. All double-blind, randomised, placebo-controlled trials that evaluated the efficacy of a combination therapy of SRIs and antipsychotics in treatment-resistant OCD were identified by systematic literature searches and combined in a meta-analysis. 11 studies with a total of 356 treatment-resistant patients were included. After the augmentation, significantly more subjects in the intervention groups (SRI + antipsychotic) fulfilled the response criterion (reduction in the Yale-Brown obsessive compulsive scale [Y-BOCS] ≥ 35 %) than in the control groups (SRI + placebo) (relative risk = 2.16). The subgroup analysis showed significant efficacy only for risperidone. Further significant differences have been found regarding the antipsychotic dosage and the SRI-treatment duration before the augmentation.
Schlüsselwörter
Zwangsstörung - Antipsychotika - Serotonin-Wiederaufnahmehemmer - Therapieresistenz - Metaanalyse
Keywords
obsessive-compulsive disorder - antipsychotics - serotonin reuptake inhibitors - treatment resistance - meta-analysis
Literatur
- 1 American Psychiatric Association (APA) .Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association. Available online at 2007 http://http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm
Reference Ris Wihthout Link
- 2
Bandelow B, Zohar J, Hollander E et al.
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the
pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress
disorders – first revision.
World J Biol Psychiatry.
2008;
9
248-312
Reference Ris Wihthout Link
- 3 National Institute for Clinical Excellence (NICE) .Obsessive compulsive disorder: Core interventions in the treatment of obsessive compulsive
disorder and body dysmorphic disorder. NICE; 2006
Reference Ris Wihthout Link
- 4
Cottraux J, Bouvard M A, Milliery M.
Combining pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive
disorder.
Cogn Behav Ther.
2005;
34
185-192
Reference Ris Wihthout Link
- 5
Eddy K T, Dutra L, Bradley R et al.
A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive
disorder.
Clin Psychol Rev.
2004;
24
1011-1030
Reference Ris Wihthout Link
- 6
Soomro G M, Altman D, Rajagopal S et al.
Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive
disorder (OCD).
Cochrane Database Syst Rev.
2008;
1
CD001765
Reference Ris Wihthout Link
- 7
Fineberg N A, Tonnoir B, Lemming O et al.
Escitalopram prevents relapse of obsessive-compulsive disorder.
Eur Neuropsychopharmacol.
2007;
17
430-439
Reference Ris Wihthout Link
- 8
Stein D J, Andersen E W, Tonnoir B et al.
Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced,
fixed-dose, 24-week study.
Curr Med Res Opin.
2007;
23
701-711
Reference Ris Wihthout Link
- 9
Dell’Osso B, Nestadt G, Allen A et al.
Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive
disorder: a critical review.
J Clin Psychiatry.
2006;
67
600-610
Reference Ris Wihthout Link
- 10
Kriegebaum C, Gutknecht L, Schmitt A et al.
Serotonin Kompakt – Teil 2: Verhaltensgenetik und Psychopathologie.
Fortschr Neurol Psychiatr.
2010;
78
332-342
Reference Ris Wihthout Link
- 11
Schmauss M, Messer T.
Therapieresistente Depressionen – Teil 1: Definition und Ursachen, Prädiktion des
Therapieerfolgs, psychotherapeutische Behandlungsstrategien.
Fortschr Neurol Psychiatr.
2010;
78
45-57
Reference Ris Wihthout Link
- 12
Pallanti S, Hollander E, Bienstock C et al.
Treatment non-response in OCD: methodological issues and operational definitions.
Int J Neuropsychopharmacol.
2002;
5
181-191
Reference Ris Wihthout Link
- 13
Pallanti S, Quercioli L.
Treatment-refractory obsessive-compulsive disorder: methodological issues, operational
definitions and therapeutic lines.
Prog Neuropsychopharmacol Biol Psychiatry.
2006;
30
400-412
Reference Ris Wihthout Link
- 14
Goodman W K, Price L H, Rasmussen S A et al.
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).
Arch Gen Psychiatry.
1989;
46
1006-1011
Reference Ris Wihthout Link
- 15
Denys D, Megen H J, derWee van N et al.
A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive
disorder.
J Clin Psychiatry.
2004;
65
37-43
Reference Ris Wihthout Link
- 16
Fallon van B A, Liebowitz M R, Campeas R et al.
Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine:
a placebo-controlled study.
Arch Gen Psychiatry.
1998;
55
918-924
Reference Ris Wihthout Link
- 17
Ninan P T, Koran L M, Kiev A et al.
High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive
disorder: a multicenter double-blind trial.
J Clin Psychiatry.
2006;
67
15-22
Reference Ris Wihthout Link
- 18
Pallanti S, Quercioli L, Koran L M.
Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open
trial.
J Clin Psychiatry.
2002;
63
796-801
Reference Ris Wihthout Link
- 19
Fink G R.
Tiefe Hirnstimulation in Neurologie und Psychiatrie.
Fortschr Neurol Psychiat.
2010;
78
69
Reference Ris Wihthout Link
- 20
Kordon A, Zurowski B, Wahl K et al.
Evidenzbasierte Pharmakotherapie und andere somatische Therapieverfahren bei Zwangsstörungen
– State of the art.
Nervenarzt.
2011;
82
319-324
Reference Ris Wihthout Link
- 21
Denys D, Zohar J, Westenberg H G.
The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.
J Clin Psychiatry.
2004;
65 (Suppl 14)
11-17
Reference Ris Wihthout Link
- 22
Goddard A W, Shekhar A, Whiteman A F et al.
Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.
Drug Discov Today.
2008;
13
325-332
Reference Ris Wihthout Link
- 23
Bloch M H, Landeros-Weisenberger A, Kelmendi B et al.
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive
disorder.
Mol Psychiatry.
2006;
11
622-632
Reference Ris Wihthout Link
- 24
Skapinakis P, Papatheodorou T, Mavreas V.
Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant
obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.
Eur Neuropsychopharmacol.
2007;
17
79-93
Reference Ris Wihthout Link
- 25
Falkai P, Wobrock T, Lieberman J et al.
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological
treatment of schizophrenia, part 2: long-term treatment of schizophrenia.
World J Biol Psychiatry.
2006;
7
5-40
Reference Ris Wihthout Link
- 26 The Cochrance Collaboration .Software Review Manager (RevMan) Version 5.1.1 2011
Reference Ris Wihthout Link
- 27
Jadad A R, Moore R A, Carroll D et al.
Assessing the quality of reports of randomized clinical trials: is blinding necessary?.
Control Clin Trials.
1996;
17
1-12
Reference Ris Wihthout Link
- 28
Bystritsky A, Ackerman D L, Rosen R M et al.
Olanzapine augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive
disorder using adjunctive olanzapine: a placebo-controlled trial.
J Clin Psychiatry.
2004;
65
565-568
Reference Ris Wihthout Link
- 29
Carey P D, Vythilingum B, Seedat S et al.
Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder:
a double-blind, randomised, placebo-controlled study.
BMC Psychiatry.
2005;
5
5
Reference Ris Wihthout Link
- 30
Denys D, Geus de F, Harold J GM et al.
A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients
with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
J Clin Psychiatry.
2004;
65
1040-1048
Reference Ris Wihthout Link
- 31
Erzegovesi S, Guglielimo E, Siliprandi F et al.
Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive
disorder: a double-blind, placebo-controlled study.
Eur Neuropsychopharmacol.
2005;
15
69-74
Reference Ris Wihthout Link
- 32
Fineberg N A, Sivakumaran T, Roberts A et al.
Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized
controlled treatment study.
Int Clin Psychopharmacol.
2005;
20
223-226
Reference Ris Wihthout Link
- 33
Hollander E, Rossi N B, Sood E et al.
Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind,
placebo-controlled study.
Int J Neuropsychopharmacol.
2003;
6
397-401
Reference Ris Wihthout Link
- 34
Kordon A, Wahl K, Koch N et al.
Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive
disorder: a double-blind, randomized, placebo-controlled study.
J Clin Psychopharmacol.
2008;
28
550-554
Reference Ris Wihthout Link
- 35
McDougle C J, Epperson C N, Pelton G H et al.
A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake
inhibitor-refractory obsessive-compulsive disorder.
Arch Gen Psychiatry.
2000;
57
794-801
Reference Ris Wihthout Link
- 36
McDougle C J, Goodman W K, Leckman J F et al.
Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder.
Arch Gen Psychiatry.
1994;
51
302-308
Reference Ris Wihthout Link
- 37
Muscatello M R, Bruno A, Pandolfo G et al.
Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine
in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled
study.
J Clin Psychopharmacol.
2011;
31
174-179
Reference Ris Wihthout Link
- 38
Shapira N A, Ward H E, Mandoki M et al.
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory
obsessive-compulsive disorder.
Biol Psychiatry.
2004;
55
553-555
Reference Ris Wihthout Link
- 39 Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press; 1969
Reference Ris Wihthout Link
- 40
Goodman W K, Storch E A, Geffken G R et al.
Obsessive-compulsive disorder in Tourette syndrome.
J Child Neurol.
2006;
21
704-714
Reference Ris Wihthout Link
- 41
Bestha D P, Jeevarakshagan S, Madaan V.
Management of tics and Tourette’s disorder: an update.
Expert Opin Pharmacother.
2010;
11
1813-1822
Reference Ris Wihthout Link
- 42
Komossa K, Depping A M, Meyer M et al.
Second-generation antipsychotics for obsessive compulsive disorder.
Cochrane Database Syst Rev.
2010;
12
CD008141
Reference Ris Wihthout Link
- 43 Higgins J PT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 The Cochrane Collaboration; 2009 Available online at http://www.cochrane-handbook.org
Reference Ris Wihthout Link
- 44
Vulink N C, Denys D, Fluitman S B et al.
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive
disorder: a randomized, double-blind, placebo-controlled study of 76 patients.
J Clin Psychiatry.
2009;
70
1001-1008
Reference Ris Wihthout Link
- 45
Goodwin G, Fleischhacker W, Arango C et al.
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus
Meeting, March 2008, Nice.
Eur Neuropsychopharmacol.
2009;
19
520-532
Reference Ris Wihthout Link
- 46
Li X, May R S, Tolbert L C et al.
Risperidone and Haloperidol Augmentation of Serotonin Reuptake Inhibitors in Refractory
Obsessive-Compulsive Disorder: A crossover study.
J Clin Psychiatry.
2005;
66
736-743
Reference Ris Wihthout Link
- 47
Matsunaga H, Nagata T, Hayashida K et al.
A long-term trial of the effectiveness and safety of atypical antipsychotic agents
in augmenting SSRI-refractory obsessive-compulsive disorder.
J Clin Psychiatry.
2009;
70
863-868
Reference Ris Wihthout Link
- 48
Kim S W, Shin I S, Kim J M et al.
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking
atypical antipsychotics: an open-label switch study.
J Clin Psychopharmacol.
2008;
28
349-352
Reference Ris Wihthout Link
- 49
Desarkar P, Das A, Nizamie S H.
Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases.
J Clin Psychopharmacol.
2007;
27
305-306
Reference Ris Wihthout Link
- 50
Ke C L, Yen C F, Chen C C et al.
Obsessive-compulsive symptoms associated with clozapine and risperidone treatment:
three case reports and review of the literature.
Kaohsiung J Med Sci.
2004;
20
295-301
Reference Ris Wihthout Link
- 51
Lykouras L, Zervas I M, Gournellis R et al.
Olanzapine and obsessive-compulsive symptoms.
Eur Neuropsychopharmacol.
2000;
10
385-387
Reference Ris Wihthout Link
- 52
Stamouli S, Lykouras L.
Quetiapine-induced obsessive-compulsive symptoms: a series of five cases.
J Clin Psychopharmacol.
2006;
26
396-400
Reference Ris Wihthout Link
- 53
Kim S W, Shin I S, Kim J M et al.
The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive
symptoms in schizophrenia.
Clin Neuropharmacol.
2009;
32
224-226
Reference Ris Wihthout Link
- 54
Metin O, Yazici K, Tot S et al.
Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an
open trial.
Hum Psychopharmacol.
2003;
18
463-467
Reference Ris Wihthout Link
- 55
Marek G J, Carpenter L L, McDougle C J et al.
Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors
in neuropsychiatric disorders.
Neuropsychopharmacology.
2003;
28
402-412
Reference Ris Wihthout Link
- 56
Koran L M, Gamel N N, Choung H W et al.
Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind
discontinuation.
J Clin Psychiatry.
2005;
66
515-520
Reference Ris Wihthout Link
- 57
Bandelow B.
The medical treatment of obsessive-compulsive disorder and anxiety.
CNS Spectr.
2008;
13
37-46
Reference Ris Wihthout Link
- 58
Maina G, Pessina E, Albert U et al.
8-week, singleblind, randomized trial comparing risperidone versus olanzapine augmentation
of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
Eur Neuropsychopharmacol.
2008;
18
364-372
Reference Ris Wihthout Link
- 59
Selvi Y, Atli A, Aydin A et al.
The comparison of aripiprazole and risperidone augmentation in selective serotonin
reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised
study.
Hum Psychopharmacol.
2011;
26
51-57
Reference Ris Wihthout Link
Dr. Markus Dold
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar
der TU München
Ismaninger Straße 22
81675 München
Email: markus.dold@lrz.tum.de